Analysts have been eager to weigh in on the Healthcare sector with new ratings on LHC Group (LHCG – Research Report), Sarepta Therapeutics (SRPT – Research Report) and Homology Medicines (FIXX – Research Report). LHC Group (LHCG) RBC Capital analyst Ben Hendrix maintained a Hold rating on LHC Group on May 16 and set a price target of $170.00. The company's shares closed last Tuesday at $165.90. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-lhc-group-lhcg-sarepta-therapeutics-srpt-and-homology-medicines-fixx?utm_source=advfn.com&utm_medium=referral
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Sarepta Therapeutics Charts.
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Sarepta Therapeutics Charts.